Molecular analysis of tuberculosis

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention relates to a molecular diagnostic method for detecting active tuberculosis (TB) in humans by measuring the levels of a specific set of RNA molecules in blood samples. The method uses gene expression profiles, focusing on the abundance of at least four (or more) particular RNAs identified as informative for distinguishing TB cases from healthy individuals. Diagnostic tools such as kits and microarrays are also provided for carrying out this blood-based molecular test. Advanced statistical algorithms (e.g., support vector machines) are applied to classify patients as having or not having active TB based on these RNA signatures.

Use CasesContent extracted from patent full text and abstract with AI.

• Rapid, non-invasive diagnosis of active tuberculosis from patient blood samples in clinical laboratories.
• Population screening for active TB in high-risk or endemic regions.
• Monitoring response to TB treatment by tracking changes in gene expression signatures over time.
• Differentiating active TB from other respiratory diseases or latent TB infection.
• Development of point-of-care testing devices for TB, based on this molecular approach.
• Use in research and clinical trials to identify early or subclinical cases of TB.
• Integration into public health programs to aid early case detection and control TB outbreaks.

BenefitsContent extracted from patent full text and abstract with AI.

• Greater sensitivity and specificity (above 80–90%) compared to traditional TB diagnostic methods, enabling more reliable detection of active disease.
• Minimally invasive, requiring only blood samples rather than sputum or tissue biopsies.
• Faster turnaround time compared to microbial cultures, leading to earlier diagnosis and treatment.
• Applicable even in cases where sputum samples are hard to obtain (e.g., young children, HIV patients).
• Scalable and suitable for high-throughput diagnostics using microarray or PCR technology.
• Potentially reduces TB transmission by enabling more cases to be identified and treated promptly.
• Facilitates personalized medicine approaches by using patient-specific molecular data.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention provides a method for molecular analysis of active tuberculosis (in short only 'TB') based on the abundance of particular RNAs from blood samples, as well as diagnostic tools such as kits and arrays suitable for such method.